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Introduction
Bacterial infection in cirrhotic patients is frequently
associated with impairment in circulatory,
hepatocellular, and renal function. Circulatory
dysfunction is characterized by arterial hypotension
and marked activation of the renin–angiotensin and
sympathetic nervous system.1 Hepatorenal syndrome
(HRS) is the most severe presentation of renal function
deterioration, caused by a decrease in effective arterial
blood volume, of which bacterial infection is the most
important precipitating factor.2 In most patients, HRS
follows a rapidly progressive course associated with a
very high hospital mortality rate, which is 4-fold
higher than that observed in patients with bacterial
infection not developing renal failure.3 Other patients
may develop a steady type of renal failure.
Cirrhosis complicated by gastroesophageal variceal
hemorrhage is characterized by high mortality and
rebleeding rates.4 Rebleeding episodes occur in
1-third of patients within 6 weeks of the index bleeding,
and more than 80% of rebleeding occurs within
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2 weeks.4,5 Gastrointestinal bleeding is associated with
bacterial infection in up to 66% of patients with
cirrhosis,6 who are vulnerable to infection because of
the disruption of the intestinal mucosal barrier and the
frequent invasive manipulations during hemorrhage.7
The close association between gastrointestinal bleeding
and infection in cirrhosis is possibly related to a trigger
of the cytokine cascade with release of vasoactive
substances, leading to increased variceal pressure and
impairment of primary hemostasis, which in turn
causes variceal bleeding.8 Bacterial infections were
recently identified as independently associated with
failure to control gastrointestinal bleeding within 5
days and associated with early rebleeding.9 A recent
randomized controlled study showed that antibiotic
prophylaxis prevented infection and rebleeding as well
as decreased the amount of blood transfused in patients
with acute variceal bleeding.10
As we have little control over the underlying liver
disease, only early detection and appropriate
management of infectious processes can be expected
to improve outcome.
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Spontaneous Bacterial Peritonitis
Definition and outcome
Spontaneous bacterial peritonitis (SBP) represents
spontaneous infection of ascitic fluid without any
apparent intra-abdominal source of infection. The
prevalence of SBP in unselected cirrhotic patients with
ascites admitted to a hospital ranges between 10% and
30%.3,11 Approximately half of the episodes of SBP are
present at the time of hospital admission.3,11 The
1-year probability for development of the first episode
of SBP in cirrhotic patients with ascites is approximately
10%.11 The outcome in cirrhotic patients with SBP has
improved dramatically during the last 20 years. In
studies published before 1980, the rate of SBP
resolution ranged between 25% and 50% and the
survival of patients ranged between 0% and 20%. The
corresponding values in recent studies are 70–90% and
50–70%, respectively.11
Pathogenesis
Several abnormalities in immune response have been
documented in the setting of cirrhosis.12,13 The
pathogen of SBP in ascitic fluid may translocate from
the intestine or blood with contamination of ascitic
fluid. A direct correlation has been found between
impairment of the local defensive mechanisms of ascites
(assessed by either the opsonic activity or the local
protein concentration in ascitic fluid) and the risk of
SBP in cirrhotic patients hospitalized with ascites.13,14
Clinical features and diagnosis
Most patients with SBP have symptoms and/or signs
clearly suggestive of peritoneal infection, especially
abdominal pain, fever, and altered gastrointestinal
motility. Other patients have no or minor symptoms
with deteriorating liver or renal function.15 SBP
diagnosis is shown in Table 1. In comparison with
conventional culture techniques, culture of ascitic
fluid directly into blood culture bottles increases the
yield of bacteria up to 90%.16 Due to the relatively low
concentration of bacteria in ascitic fluid compared
with infections in other organic fluid (e.g. urine), the
minimum amount of ascitic fluid inoculated into each
bottle should be 10 mL.16 A new leukocyte esterase
reagent strip is reported to be a rapid, easy-to-use and
inexpensive tool for bedside diagnosis of SBP.17,18
Special conditions other than SBP
Culture-negative neutrocytic ascites (CNNA) is
diagnosed when the ascitic fluid culture does not grow
pathogenic bacteria, the ascitic fluid neutrophil count
is at least 250/mm3, and there is no evident intra-
abdominal surgically treatable source of infection.
CNNA is considered a variant of SBP since they share
the same short- and long-term course.19
Table 1. Recommendations on diagnosis of spontaneous bacterial peritonitis (SBP) and special conditions
Diagnosis of SBP
1. Ascitic fluid polymorphonuclear neutrophil (PMN) count > 250/mm3; in patients with bloody ascites, subtract 1 PMN
per 250 red blood cells
2. Cultures
- Ascitic fluid cultures: bedside inoculation into blood culture bottles (* 10 mL)
- Blood cultures: simultaneous to ascitic fluid cultures
Special conditions
1. Bacterascites: positive ascitic fluid culture, ascites PMN < 250/mm3, and no evidence of local or systemic infection
- Repeat paracentesis once bacterascites is diagnosed and initiate antibiotic if:
• Ascites PMN > 250/mm3
• Ascites PMN < 250/mm3, but culture continues to be positive
2. Secondary peritonitis: suspected when any of the following:
- Lack of response to antibiotic treatment
- Two or more organisms isolated (particularly anaerobes or fungi)
- At least 2 of the following findings in ascitic fluid:
• glucose < 50 mg/dL; protein > 10 g/L; lactate dehydrogenase > normal serum levels
Once secondary peritonitis is suspected:
- Initiate appropriate radiologic investigation
- Add antibiotics against anaerobes and enterococci
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Bacterascites is diagnosed as in Table 1. It is a
prerequisite to the development of SBP or a transient
and spontaneously reversible colonization of ascites.20
Secondary peritonitis is caused by perforation or
acute inflammation of intra-abdominal organs,
abdominal wall infections, or previous abdominal
surgical procedures.15,21,22 Differentiation between
primary and secondary peritonitis is important because
secondary peritonitis usually does not resolve unless
patients are treated surgically. Conversely, surgical
therapy may be accompanied by significant
deterioration in the clinical status of cirrhotic patients
with SBP.23
Treatment
Empiric antibiotic therapy must be initiated
immediately after the diagnosis is made. Initial antibiotic
therapy should cover Enterobacteriaceae and non-
enterococcal Streptococcus spp.16 Recently, infections
caused by Gram-positive cocci have markedly increased
in cirrhosis, probably because of the current high
degree of instrumentation of cirrhotic patients and
long-term norfloxacin prophylaxis.24
Cefotaxime is the most extensively investigated
parenteral antibiotic in patients with SBP. Two
comparative studies reported that cefotaxime was
more effective than ampicillin plus tobramycin or
aztreonam in the treatment of SBP, with higher
resolution rates and less nephrotoxicity and fewer
superinfections.25,26 Another 2 controlled trials
showed that the optimal cefotaxime regimen in
cirrhotic patients was 5-day therapy with cefotaxime
2 g, 3 times daily.25,27 Other cephalosporins, including
cefonicid, ceftriaxone and ceftazidime, are as effective
as cefotaxime in improving SBP resolution and patient
survival.28,29
In patients with non-severely complicated SBP
(no septic shock, ileus, or serum creatinine > 3 mg/
dL), oral ofloxacin (400 mg/12 hours) can be as
effective as cefotaxime (2 g/6 hours) with similar
rates of infection resolution, patient survival and
superinfection.30 Another comparative trial also
showed that amoxicillin–clavulanic acid was as effective
as cefotaxime in the treatment of SBP, without
relevant adverse effects.31
Sort et al demonstrated that, in patients with SBP,
treatment with intravenous albumin plus antibiotics
reduced the incidence of renal impairment and
improved hospital survival.32 Albumin was given at a
dose of 1.5 g/kg of body weight at the time of
diagnosis, followed by 1 g/kg of body weight on day
3. Renal impairment (10% vs 33%) and hospital
mortality (10% vs 29%) were significantly lower with
cefotaxime plus albumin than with cefotaxime alone.
The beneficial effects of albumin administration on
systemic hemodynamics and renal function in SBP are
related to both an improvement in cardiac function
and a decrease in the degree of arterial vasodilatation.33
Prophylaxis
Cirrhotic patients recovering from an episode of SBP
or during a gastrointestinal bleeding episode should
receive prophylaxis against bacterial infection.6 The
probability of SBP recurrence is approximately 70% 1
year after resolution of the first SBP episode.17 Previous
studies have found no differences between orally
administered (per os or through a nasogastric tube)
versus intravenously administered antibiotics.34,35
A concern with the use of prolonged antibiotic
prophylaxis is that it will lead to selection of antibiotic-
resistant bacteria.36 One recent study showed that
about 2-thirds of infections in untreated cirrhotic
patients were due to Gram-negative organisms, while
infections in patients receiving quinolone prophylaxis
were mostly due to Gram-positive organisms.36,37 Thus,
antibiotic is only necessary in patients at greatest risk
of SBP (Table 2).38 Finally, it should be kept in mind
that cirrhotic patients with recurrent SBP have a poor
prognosis. The 1- and 2-year probability of survival
after an episode of SBP are 30–50% and 25–30%,
respectively.3 Since survival expectancy after liver
transplantation is high, patients recovering from an
episode of SBP should be considered as potential
candidates for liver transplantation.
Table 2. Recommendations on prophylaxis of spontaneous bacterial peritonitis (SBP)
In cirrhotics with upper gastrointestinal hemorrhage
1. Oral administration of norfloxacin 400 mg/12 hours for * 7 days
2. Alternative regimens: combinations of systemic antibiotics (ciprofloxacin, ofloxacin, amoxicillin–clavulanic acid)
In non-bleeding cirrhotic patients with ascites
1. Recovering from first SBP episode: continuous oral administration of norfloxacin 400 mg/day
2. Without history of SBP but low ascitic fluid protein (< 10 g/L): no consensus on the necessity of prophylaxis
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Other Infections
Urinary tract infections
Urinary tract infections (UTIs) in cirrhosis are usually
asymptomatic, and bacteriuria alone is found in a high
proportion of UTI episodes in cirrhotics. Its potential
role in causing bacteremia may be underestimated.
The incidence is markedly higher in cirrhotics with
indwelling catheters and female cirrhotics.39 Thus,
empiric administration of a modern quinolone
(norfloxacin, ofloxacin or ciprofloxacin) or amoxicillin–
clavulanic acid or oral cephalosporin should be
considered in high-risk patients.3,39
Pneumonia
Community-acquired pneumonia is a frequent
complication in subjects with active alcoholism.40
Streptococcus pneumoniae is the causative organism in
most lower respiratory tract infections in alcoholics.
However, other pathogens normally present in the
oropharyngeal area, especially anaerobic bacteria or
Haemophilus influenzae, Klebsiella pneumoniae,
mycoplasma pneumonia, or Legionella spp., have also
been reported.40 In these subjects, empiric antibiotics
could include erythromycin combined with 1 of the
following: cefotaxime, ceftriaxone, amoxicillin–
clavulanic acid, or imipenem. Hospital-acquired
pneumonia is mainly caused by Gram-negative bacilli
and Staphylococci.41 Some procedures or clinical
conditions, such as tracheal intubation, esophageal
tamponade, and hepatic encephalopathy, are clearly
predisposing factors for pneumonia in cirrhotic patients.
The empiric antibiotic for these subjects is the third-
generation cephalosporins (i.e. cefotaxime). If aspiration
is suspected, clindamycin should be added.41
Cirrhotic patients with hydrothorax can develop
spontaneous bacterial empyema, which is thought to
have the same pathogenesis as SBP, since their isolated
bacteria are the same.42 Therefore, patients with
spontaneous bacterial empyema may be treated with
the same antibiotic regimens.
Endocarditis
Endocarditis complicating the course of cirrhosis
usually arises from a previously normal endocardium.
Streptococcus spp. (Streptococcus viridans, Streptococcus
enterococcus, Streptococcus bovis) and Staphylococcus
aureus are the most common causative organisms, but
the possibility of endocarditis caused by enterobacteria
should not be underestimated.43
Soft-tissue infections
Lymphangitis of the lower extremities and abdominal
wall are frequent in cirrhotic patients with ankle edema
and ascites. Although S. aureus and Streptococcus
pyogenes are the most frequent causative organisms,
Enterobacteriaceae and anaerobes may also complicate
these infections.44 Amoxicillin–clavulanic acid may be
an adequate empiric antibiotic treatment. More
recently, quinolones such as ofloxacin have been
proposed for the treatment of soft-tissue infections.
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